deltatrials
Completed PHASE4 NCT00242411

MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults

A Comparison of the Efficacy of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 Inhalation b.i.d. Plus As-needed) and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults. A Randomized, Open, Parallel-group, Multicentre 26-weeks Study

Sponsor: AstraZeneca

Conditions Asthma
Interventions Budesonide/Formoterol Turbuhaler Conventional Best Asthma Therapy
Updated 6 times since 2017 Last updated: Jan 21, 2011 Started: Sep 30, 2004 Primary completion: Oct 31, 2006 Completion: Oct 31, 2006

Listed as NCT00242411, this PHASE4 trial focuses on Asthma and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aabenraa, Denmark, Aalborg, Denmark, Aksdal, Norway, Albertslund, Denmark, Allingåbro, Denmark, Anjalankoski, Finland, Arendal, Norway, Asker, Norway, Bagsværd, Denmark, Ballerup Municipality, Denmark and 169 more location s